Trial Profile
A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Aug 2011 New trial record